Is plasma cardiotrophin-1 a marker of hypertensive heart disease?

OBJECTIVE: This study was designed to investigate whether plasma concentration of cardiotrophin-1 (CT-1), a cytokine that induces cardiomyocyte hypertrophy and stimulates cardiac fibroblasts, is related to hypertensive heart disease, as defined by the presence of echocardiographically assessed left...

ver descrição completa

Detalhes bibliográficos
Autores: Lopez-Salazar, M.B. (María Begoña)|||/items/153e0e37-14b0-403e-afab-8af00c4edde0, Gonzalez, A. (Arantxa)|||/items/9c64c0f4-66b4-4b51-8593-0e50c091a515, Lasarte-Sagastibelza, J.J. (Juan José)|||/items/e366ad83-3db4-41ec-a9da-ed9159ba5c0c, Sarobe, P. (Pablo)|||/items/e6f6a7ac-cfe2-409e-ab14-057dea5fd160, Borras-Cuesta, F. (Francisco)|||/items/9f3719bd-4cf6-4e5b-b672-39179b54e8cc, Díaz-Dorronsoro, I. (Inés)|||/items/eb812d3a-1796-4950-b894-c77b1b522c41, Barba, J. (Joaquín)|||/items/7ba5bad3-fc2c-4be1-9498-95083555fc81, Tomas, L. (Lourdes)|||/items/cd279eb6-fd63-4615-8676-8ab4cfea0747, Lozano, E. (Elisa)|||/items/bf101e02-aadc-4ab0-8d02-d55a63a23be9, Serrano, M. (Manuel)|||/items/f8a0b6a3-32b3-46e5-baaa-dfd3eb1f92c9, Varo-Cenarruzabeitia, N. (Nerea)|||/items/18b5a757-44b9-4e23-8a8c-ad907969001f, Beloqui, O. (Óscar)|||/items/87d04a14-2d74-4221-8a57-12550777420d, Fortuño-Cebamanos, M.A. (María Antonia)|||/items/4dc78327-206a-4160-a352-90965670b0ec, Diez-Martinez, J. (Javier)|||/items/4f3a0e43-12bf-403d-9dc7-31fab0d11d41
Formato: artículo
Fecha de publicación:2005
País:España
Recursos:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/19914
Acesso em linha:https://hdl.handle.net/10171/19914
Access Level:acceso abierto
Palavra-chave:Cardiotrophin-1
Hypertensive heart disease
Left ventricular
Descrição
Resumo:OBJECTIVE: This study was designed to investigate whether plasma concentration of cardiotrophin-1 (CT-1), a cytokine that induces cardiomyocyte hypertrophy and stimulates cardiac fibroblasts, is related to hypertensive heart disease, as defined by the presence of echocardiographically assessed left ventricular hypertrophy (LVH). METHODS: The study was performed in 31 normotensive subjects and 111 patients with never-treated essential hypertension (54 without LVH and 57 with LVH). Causes of LVH other than hypertension were excluded after a complete medical workup. A novel enzyme-linked immunosorbent assay was developed to measure plasma CT-1. RESULTS: Plasma CT-1 was increased (P < 0.001) in hypertensives compared with normotensives. The value of CT-1 was higher (P < 0.001) in hypertensives with LVH than in hypertensives without LVH. Some 31% of patients without LVH exhibited values of CT-1 above the upper normal limit in normotensives. A direct correlation was found between CT-1 and left ventricular mass index (r = 0.319, P < 0.001) in all subjects. Receiver operating characteristic curves showed that a cutoff of 39 fmol/ml for CT-1 provided 75% specificity and 70% sensitivity for predicting LVH with a relative risk of 6.21 (95% confidence interval, 2.95 to 13.09). CONCLUSIONS: These results show an association between LVH and the plasma concentration of CT-1 in essential hypertension. Although preliminary, these findings suggest that the determination of CT-1 may be an easy and reliable method for the initial screening and diagnosis of hypertensive heart disease.